With a prevalence of 34% (55/162 at-risk recipients) and a mortality of 25% (14/55 affected recipients), obliterative bronchiolitis is the most significant long-term complication after pulmonary transplantation. Because of its importance, we examined donor-recipient characteristics and antecedent clinical events to identify factors associated with development of obliterative bronchiolitis, which might be eliminated or modified to decrease its prevalence. We also compared treatment outcome between recipients whose diagnosis was made early by surveillance transbronchial lung biopsy before symptoms or decline in pulmonary function were present versus recipients whose diagnosis was made later when symptoms or declines in pulmonary function were...
BACKGROUND: Lung transplant (LTx) recipients have low long-term survival and a high incidence of bro...
Bronchiolitis obliterans (BO) is a serious pulmonary complication after allogeneic hematopoietic ste...
Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell...
With a prevalence of 34% (55/162 at-risk recipients) and a mortality of 25% (14/55 affected recipien...
AbstractObjective: This study identifies specific clinical and immunologic factors in lung transplan...
The clinical significance of minimal acute rejection (grade A,) in lung transplant recipients is unk...
Bronchiolitis obliterans syndrome (BOS) remains a major complication after lung transplantation, cau...
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
main chronic complication after heart-lung (HLTx) and lung transplantation (LTx), limiting the long-...
Overall Goals and Objectives: 1. Understand the risk factors for Bronchiolitis Obliterans Syndrome a...
The diagnosis of the obliterative bronchiolitis syndrome in lung transplantation is presently best e...
RationaleLung transplantation offers great promise for otherwise terminal lung diseases, but the dev...
Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival af...
Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival af...
ObjectivesIn 2005, the time-based waiting list for lung transplantation was replaced by an illness/b...
BACKGROUND: Lung transplant (LTx) recipients have low long-term survival and a high incidence of bro...
Bronchiolitis obliterans (BO) is a serious pulmonary complication after allogeneic hematopoietic ste...
Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell...
With a prevalence of 34% (55/162 at-risk recipients) and a mortality of 25% (14/55 affected recipien...
AbstractObjective: This study identifies specific clinical and immunologic factors in lung transplan...
The clinical significance of minimal acute rejection (grade A,) in lung transplant recipients is unk...
Bronchiolitis obliterans syndrome (BOS) remains a major complication after lung transplantation, cau...
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
main chronic complication after heart-lung (HLTx) and lung transplantation (LTx), limiting the long-...
Overall Goals and Objectives: 1. Understand the risk factors for Bronchiolitis Obliterans Syndrome a...
The diagnosis of the obliterative bronchiolitis syndrome in lung transplantation is presently best e...
RationaleLung transplantation offers great promise for otherwise terminal lung diseases, but the dev...
Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival af...
Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival af...
ObjectivesIn 2005, the time-based waiting list for lung transplantation was replaced by an illness/b...
BACKGROUND: Lung transplant (LTx) recipients have low long-term survival and a high incidence of bro...
Bronchiolitis obliterans (BO) is a serious pulmonary complication after allogeneic hematopoietic ste...
Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell...